Lucid Diagnostics Plunges 14.39% on Share Sale Plan

On June 2, 2025, Lucid Diagnostics experienced a significant drop of 14.39% in pre-market trading.

Lucid Diagnostics' stock price decline can be attributed to the company's announcement that it may offer to sell shares of common stock of up to $25 million. This news has raised concerns among investors about potential dilution of existing shares, leading to a sell-off in the stock.

Investors are closely monitoring the situation as the company navigates through this challenging period. The market's reaction highlights the sensitivity of stock prices to corporate actions that could impact shareholder value.